Literature DB >> 11245639

Effects of urotensin II in human arteries and veins of varying caliber.

C Hillier1, C Berry, M C Petrie, P J O'Dwyer, C Hamilton, A Brown, J McMurray.   

Abstract

BACKGROUND: -Urotensin II (UII) is the ligand for the GPR14 receptor and the most potent vasoconstrictor in the cynomolgus monkey. UII also contracts rat thoracic aorta. We studied the effect of human UII (hUII) in human blood vessels Methods and Results-Small subcutaneous resistance arteries, internal mammary arteries, saphenous veins, and small subcutaneous veins were studied using standard techniques. Subcutaneous resistance arteries constricted in response to norepinephrine (maximum tension, 2.84+/-0.38 mN/mm; the concentration required to produce 50% of the maximum response [EC(50)], 0.52+/-0.07 micromol/L) and endothelin-1 (maximum tension, 4.19+/-0.93 mN/mm; EC(50), 1.6+/-0.1 nmol/L). hUII did not contract these arteries, internal mammary arteries, or either type of vein, but it was a potent vasoconstrictor in rat thoracic aorta (maximum tension, 2.36+/-0.2 mN/mm; EC(50), 1.13+/-0.36 nmol/L).
CONCLUSIONS: -hUII has no vasoconstrictor action in human arteries and veins of different sizes and vascular beds. Marked species differences in the actions of UII question its importance in human cardiovascular regulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245639     DOI: 10.1161/01.cir.103.10.1378

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

1.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

2.  Urotensin II alters vascular reactivity in animals subjected to volume overload.

Authors:  Gregory S Harris; Robert M Lust; Laxmansa C Katwa; Christopher J Wingard
Journal:  Peptides       Date:  2010-08-17       Impact factor: 3.750

Review 3.  Regulation of Coronary Blood Flow.

Authors:  Adam G Goodwill; Gregory M Dick; Alexander M Kiel; Johnathan D Tune
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

4.  Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension.

Authors:  Yavuz Pehlivan; Recep Dokuyucu; Tuncer Demir; Davut Sinan Kaplan; Ibrahim Koc; Mustafa Orkmez; Ibrahim Halil Turkbeyler; Ali Osman Ceribasi; Ediz Tutar; Seyithan Taysi; Bunyamin Kisacik; Ahmet Mesut Onat
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

Review 5.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 6.  Is urotensin-II the new endothelin?

Authors:  Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

7.  Urotensin II evokes potent vasoconstriction in humans in vivo.

Authors:  Felix Böhm; John Pernow
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

8.  The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.

Authors:  M Skinner; K Philp; D Lengel; L Coverley; E Lamm Bergström; P Glaves; H Musgrove; H Prior; M Braddock; R Huby; J O Curwen; P Duffy; A R Harmer
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

9.  Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries.

Authors:  R T Bennett; R D Jones; A H Morice; C F C Smith; M E Cowen
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

10.  No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans.

Authors:  Jonathan T Affolter; David E Newby; Ian B Wilkinson; Matthew J Winter; Richard J Balment; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.